LUClNDA B. BARNARD, M.D.; GRANTHAM WILLIAM G., M.D., Ph.D.; PRESTON LAMBERTON, M.D.; THOMAS M. O'DORISIO, M.D.; IVOR M. D. JACKSON, M.R.C.P.
Six patients with resistant acromegaly were given a longacting somatostatin analogue (SMS 201-995) for 5 to 12 months. The clinical response was dramatic; relief of headache occurred within minutes of the injection. The mean 24-hour growth hormone levels fell acutely after the administration of 50 or 100 µg every 12 hours, especially in four patients with small tumors (p < 0.001). Dosages of up to 1500 µg/d were necessary to produce maximum lowering of growth hormone secretion in some patients. On long-term treatment, plasma somatomedin-C levels fell in all patients and became normal in four. Plasma immunoreactive levels of SMS 201-995 related inversely to growth hormone concentration: A reproducible threshold for growth hormone inhibition in five of the patients, ranging from 70 to 1200 pg/mL, was maintained for 6 to 8 hours after the injections. This somatostatin analogue is effective in the treatment of acromegaly, has no major side effects, and causes only transient changes in carbohydrate metabolism.
Learn more about subscription options.
Register Now for a free account.
BARNARD LB, WILLIAM G. G, LAMBERTON P, O'DORISIO TM, JACKSON IMD. Treatment of Resistant Acromegaly with a Long-Acting Somatostatin Analogue (SMS 201-995). Ann Intern Med. 1986;105:856–861. doi: 10.7326/0003-4819-105-6-856
Download citation file:
Published: Ann Intern Med. 1986;105(6):856-861.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only